TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cell-based immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that Dr. Miguel Forte, Sr. VP Clinical Development and Regulatory Affairs, TxCell, will present on T cellular therapy for autoimmune diseases at the 7th National Bio-Therapy Conference, October 24-26, 2014 at Great Tang Hotel, Shanghai, China.
Press Releases is unique and effective promotional tool offered from Worldpharmatoday.com aimed at bringing our client’s business message into limelight and more importantly make it reach their target audience. This feature can be utilized to launch new product, promoting existing Pharma product, publish business agreements, annual reports, financial results, corporate performances, important announcements or any important information that has to be conveyed to the target audience.
To add free press releases please click here.
Endo International has persuaded Auxilium Pharma into a takeover that leaves an earlier plan to merge Auxilium with QLT in tatters.
Ireland-based Endo has made a $2.6bn cash-and-stock offer for Auxilium - which has been approved by the boards of both companies - that will add the latter's portfolio of testosterone replacement therapies to Endo fast-growing speciality pharma business.
Pharming to Directly Commercialise Ruconest in Austria Germany and Netherlands
Biotech company Pharming Group NV ("Pharming" or "the Company") (EURONEXT: PHARM) and Swedish Orphan Biovitrum AB (publ) or "Sobi" (SS: SOBI) today announced the amendment and extension of the Ruconest® distribution agreement between Pharming and Sobi. Effective immediately Pharming will focus on direct commercialization in Austria Germany and Netherlands and Sobi will extend its Ruconest® sales territory with the addition of Azerbaijan Belarus Georgia Kazakhstan Russia Serbia and Ukraine.
Therapure Biopharma is appearing at the upcoming BioProcess International Conference & Exhibition.
Boehringer Ingelheim Pharmaceuticals has introduced Striverdi Respimat (olodaterol) inhalation spray 5µg in the US market.
Eyeforpharma, London, September 2014: Mary Baker, immediate past President of the European Brain Council, believes that pharma companies are focusing too much on patient centricity and instead, should widen their focus to include the whole of society.
France-based D&A Pharma has entered into an exclusive supply, licensing and distribution agreement with Grupo Juste for Alcover, sodium oxybate, a treatment for alcohol dependence.
Patheon is to showcase its biologic, small molecule API development services and manufacturing capabilities for finished dosage forms at CPhI / ICSE Worldwide from Tuesday 7 October to Thursday 9 October in Paris Nord Villepinte, France.
Pfanstiehl Launches cGMP-produced Mannose for Cell Culture Media Optimization and Glycoprotein Biosynthesis
Pfanstiehl has announced the launch of cGMP-produced, high purity Mannose (USP/NF, EP), manufactured in the US under ICH Q7 compliant conditions.
nLife Therapeutics, an early-stage biopharmaceutical company leading developments in nOligos (neuronal specific oligonucleotides) as therapeutic agents for CNS disorders, today announces that The Michael J. Fox Foundation for Parkinson’s Research (MJFF) has awarded the company a grant of USD 350,000 (EUR 271,000). nLife will conduct a research study entitled: “Pharmacokinetic and Pharmacodynamic characterization of a novel therapy to silence selectively alpha-synuclein in monoaminergic neurons of rat.”
Page 1 of 64